A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers

Vaccine

Volumn 28, Issue 36, 2010, Pages 5845-5849

  Jang, Hee Chang ^a   Kim, Choong Jong ^a   Kim, Kye Hyoung ^a   Lee, Kwang Hee ^b   Byun, Young Ho ^b   Seong, Baik Lin ^b   Saletti, Giulietta ^c   Czerkinsky, Cecil ^c   Park, Wan Beom ^a   Park, Sang Won ^a   Kim, Hong Bin ^a   Kim, Nam Joong ^a   Oh, Myoung don ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c International Vaccine Institute   (South Korea)

Author keywords

Efficacy; Immunity; Smallpox vaccine

Indexed keywords

CJ 50300; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSPNEA; ECZEMA; ECZEMA VACCINATUM; ENCEPHALITIS; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; KERATITIS; LOW DRUG DOSE; LYMPH NODE PAIN; MALE; NORMAL HUMAN; PAPULE; PERICARDITIS; PRIORITY JOURNAL; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; SMALLPOX; SMALLPOX VIRUS; THORAX PAIN; VACCINIA;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; NEUTRALIZATION TESTS; SMALLPOX; SMALLPOX VACCINE; YOUNG ADULT;

EID: 77955552937     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.063     Document Type: Article

References (23)

1. Grabenstein J.D., Winkenwerder W. US military smallpox vaccination program experience. JAMA 2003, 289(24):3278-3282.
2. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis 2003, 37(2):241-250.
3. Weltzin R., Liu J., Pugachev K.V., Myers G.A., Coughlin B., Blum P.S., et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 2003, 9(9):1125-1130.
4. Greenberg R.N., Kennedy J.S., Clanton D.J., Plummer E.A., Hague L., Cruz J., et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005, 365(9457):398-409.
5. Artenstein A.W., Johnson C., Marbury T.C., Morrison D., Blum P.S., Kemp T., et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 2005, 23(25):3301-3309.
6. Kim S.H., Choi S.J., Park W.B., Kim H.B., Kim N.J., Oh M.D., et al. Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 2007, 25(33):6287-6291.
7. ACAM2000 Smallpox vaccine. Smallpox Vaccine Vaccines and Related Biological Products Advisory Committee (VRBPAC) Briefing Document. Reported 18 April 2007. Available at: Accessed 27 January 2010. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292B2-02.pdf.
8. Investigator's brochure for CJ-50300. Seoul, South Korea; March 2006.
9. Rotz L.D., Dotson D.A., Damon I.K., Becher J.A. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001, 50(RR-10):1-25. quiz; CE1-7.
10. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002, 346(17):1265-1274.
11. Frey S.E., Newman F.K., Yan L., Lottenbach K.R., Belshe R.B. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003, 289(24):3295-3299.
12. Kim S.H., Yeo S.G., Jang H.C., Park W.B., Lee C.S., Lee K.D., et al. Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial. J Infect Dis 2005, 192(6):1066-1070.
13. Talbot T.R., Stapleton J.T., Brady R.C., Winokur P.L., Bernstein D.I., Germanson T., et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004, 292(10):1205-1212.
14. Kim S.H., Yeo S.G., Cho J.H., Kim H.B., Kim N.J., Oh M.D., et al. Cell-mediated immune responses to smallpox vaccination. Clin Vaccine Immunol 2006, 13(10):1172-1174.
15. Kim S.H., Bang J.W., Park K.H., Park W.B., Kim H.B., Kim N.J., et al. Prediction of residual immunity to smallpox, by means of an intradermal skin test with inactivated vaccinia virus. J Infect Dis 2006, 194(3):377-384.
16. Rock M.T., Yoder S.M., Talbot T.R., Edwards K.M., Crowe J.E. Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. J Infect Dis 2006, 194(4):435-443.
17. Kennedy J.S., Frey S.E., Yan L., Rothman A.L., Cruz J., Newman F.K., et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 2004, 190(7):1286-1294.
18. Frey S.E., Newman F.K., Cruz J., Shelton W.B., Tennant J.M., Polach T., et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002, 346(17):1275-1280.
19. Frey S.E., Newman F.K., Kennedy J.S., Ennis F., Abate G., Hoft D.F., et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009, 27(10):1637-1644.
20. Bryant-Genevier M., O'Connell K., Ball R., Braun M.M., McMahon A. Passive surveillance for generalized vaccinia in the United States using the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2006, 24(17):3632-3635.
21. Beigel J., Kohl K.S., Brinley F., Graham P.L., Khuri-Bulos N., LaRussa P.S., et al. Generalized vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5745-5753.
22. Talbot T.R., Bredenberg H.K., Smith M., LaFleur B.J., Boyd A., Edwards K.M. Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. JAMA 2003, 289(24):3290-3294.
23. Note for guidance on the development of vaccinia virus based vaccines against smallpox. The European Agency for the Evaluation of Medical Products (EMEA)/Committee for Proprietary Medicinal Products (CPMP) guidance document. Available at: http://www.ema.europa.eu/pdfs/human/vwp/110002en.pdf. Accessed 1 June 2010. http://www.ema.europa.eu/pdfs/human/vwp/110002en.pdf.